Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Age≥18 years

          -  Histologically or cytologically confirmed advanced non-small cell lung cancer

          -  Must have evidence of c-Met positivity from the results of molecular pre-screening
             evaluations

          -  At least one measurable lesion as per RECIST v1.1

          -  Patients must have recovered from all toxicities related to prior anticancer therapies
             to grade ≤ 1

          -  ECOG Performance Status of 0-2

        Exclusion Criteria:

          -  Previous or current treatment with a c-Met inhibitor or HGF-targeting therapy

          -  Symptomatic central nervous system (CNS) metastases that are neurologically unstable
             or requiring increasing doses of steroids to control, and patients with any CNS
             deficits.

          -  Clinically significant, uncontrolled heart diseases. Unstable angina History of
             documented congestive heart failure (New York Heart Association functional
             classification > II) Uncontrolled hypertension defined by a Systolic Blood Pressure
             (SBP) ≥ 140 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 90 mm Hg Arrhythmias

          -  Active peptic ulcer disease or gastritis

          -  Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1,
             except for alopecia

          -  Major surgery within 4 weeks prior to starting PLB1001

          -  Previous anti-cancer and investigational agents within 4 weeks before first dose of
             PLB1001. If previous treatment is a monoclonal antibody, then the treatment must be
             discontinued at least 6 weeks before first dose of PLB1001.

          -  Pregnant or nursing women

          -  Involved in other clinical trials < 30 days prior to Day 1